Wealthspire Advisors (New York)’s Recursion Pharmaceuticals RXRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.3K	Buy	14,535 +2,000	+16%	+$6.66K	﹤0.01%	1250
2026 Q1	$38.5K	Sell	12,535 -300	-2%	-$1.16K	﹤0.01%	913
2025 Q4	$52.5K	Sell	12,835 -231	-2%	-$1.14K	﹤0.01%	1024
2025 Q3	$63.8K	Sell	13,066 -927	-7%	-$4.87K	﹤0.01%	1152
2025 Q2	$70.8K	Buy	13,993 +1,508	+12%	+$7.41K	﹤0.01%	831
2025 Q1	$66K	Hold	12,485	–	–	﹤0.01%	771
2024 Q4	$84.4K	Buy	12,485 +1,158	+10%	+$7.79K	﹤0.01%	772
2024 Q3	$74.6K	Sell	11,327 -1,000	-8%	-$7.17K	﹤0.01%	732
2024 Q2	$92.5K	Buy	12,327 +1,000	+9%	+$8.72K	﹤0.01%	642
2024 Q1	$113K	Hold	11,327	–	–	﹤0.01%	624
2023 Q4	$112K	Hold	11,327	–	–	﹤0.01%	631
2023 Q3	$86.7K	Buy	+11,327	New	+$113K	﹤0.01%	582

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealthspire Advisors (New York)'s RXRX Position: Q2 2026 in Review

Wealthspire Advisors (New York) increased its Recursion Pharmaceuticals (RXRX) stake by 16% in Q2 2026, buying an estimated $6.66K and bringing the position to 14,535 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

Wealthspire Advisors (New York) first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $113K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Wealthspire Advisors (New York) held 14,535 shares of Recursion Pharmaceuticals worth $53.3K as of Q2 2026.
Wealthspire Advisors (New York) bought 2,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $6.66K.
Recursion Pharmaceuticals made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1250 holding.
Wealthspire Advisors (New York) first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Wealthspire Advisors (New York)'s Recursion Pharmaceuticals position peaked at $113K in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.